Inovio Files European Application for Its Drug After U.S. Approval, With Launch Planned for 2027
Key Facts
Inovio submitted a conditional marketing authorization application to the European Medicines Agency on November 18 for its drug VOCERYQ to treat adults with recurrent respiratory papillomatosis, opening a European regulatory path after the treatment received accelerated approval in the United States. The company said the region currently has no approved nonsurgical treatment option targeting the cause of the disease. The U.S. Food and Drug Administration granted the drug approval on October 30 to reduce the frequency of surgeries needed to remove growths. The agency described it as the first plasmid DNA-based immunotherapy to receive approval in the United States. The European application puts regulatory expansion alongside preparations to market the treatment in the U.S. market.
U.S. approval of VOCERYQ does not mean Inovio has already launched it commercially. The company expects the treatment to be available for ordering and shipment in the United States about 60 days after the October 30 approval, with a full commercial launch planned for the first quarter of 2027. It also said its inventory and manufacturing capacity are expected to be sufficient to support the first year of the launch in 2027. This plan separates the start of product availability from the full commercial launch, which the company set for a later date. The November 18 announcement did not confirm that ordering and shipment had begun.
The FDA approval was based on an open-label, multicenter trial involving 32 adults with the disease. Of the 26 patients who had undergone three or more baseline surgeries, 7 patients, or 27%, needed no surgical intervention during the first year after treatment, according to the agency. The drug targets HPV-6 and HPV-11, the viruses Inovio said cause the disease, and is administered using the CELLECTRA 5PSP device. This is part of a treatment intended to reduce the frequency of surgeries, not a description of an outcome beyond what the trial observed. The approval remains accelerated, making results from the confirmatory study part of subsequent regulatory requirements.
The approval letter required a confirmatory study involving at least 50 adult and pediatric patients, with surgical interventions followed for at least 3 years. The FDA set December 30, 2026, as the deadline for submitting a draft protocol, and June 30, 2027, for submitting the final protocol. The agency also said the company is required to conduct post-approval clinical trials to verify and describe the clinical benefit. Accelerated approval was based on an intermediate clinical endpoint expected to predict clinical benefit. Continued approval may depend on verifying that benefit in post-marketing confirmatory studies.
The European step coincides with Inovio's move into a commercial phase after U.S. approval. Chief Executive Jacqueline Shea said the company's primary goal is to make VOCERYQ the preferred first-line immunotherapy for patients with recurrent respiratory papillomatosis. She added that the public offering provides additional financial resources to support the launch. In the third quarter of 2026, research and development expenses fell to $10.6 million from $13.3 million in the same period of 2025, while general and administrative expenses rose to $9.2 million from $7.9 million. The company attributed the increase in administrative expenses to preparations for the VOCERYQ launch.
The company posted a net loss of $49.2 million in the third quarter of 2026, compared with a loss of $45.5 million in the same period of 2025, according to its announcement on November 10. Inovio attributed the wider loss mainly to a non-cash loss of $26.9 million from remeasuring the fair value of warrant liabilities. It said cash, cash equivalents and short-term investments will support operations through late in the fourth quarter of 2027. The liquidity estimate includes net proceeds of $80.5 million from a November offering, $10.9 million from warrant exercises after September 30, and estimated net operating cash burn of $21.0 million in the fourth quarter of 2026. INO shares closed at $1.63 on November 17, according to EL7 data.